194 related articles for article (PubMed ID: 32113839)
21. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
Zhang M; Qi C; Zha Y; Chen J; Luo P; Wang L; Sun Z; Wan J; Xing C; Wang S; Jiang G; Sun M; Chen Q; Chen J; Li D; Guan T; Ni Z
Clin Rheumatol; 2019 Mar; 38(3):859-867. PubMed ID: 30426311
[TBL] [Abstract][Full Text] [Related]
22. Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy.
Wang M; Zhang P; Lin W; Fei Y; Chen H; Li J; Zhang L; Zheng W; Li Y; Zeng X; Zhou J; Lai Y; Liu X; Xue H; Cui Y; Zhou L; Zhao J; Zhang W
Arthritis Res Ther; 2019 Feb; 21(1):44. PubMed ID: 30709411
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT.
Stouten V; Michiels S; Westhovens R; De Cock D; Belba A; Pazmino S; Van der Elst K; Joly J; Verschueren P
Clin Rheumatol; 2020 Sep; 39(9):2593-2601. PubMed ID: 32166429
[TBL] [Abstract][Full Text] [Related]
24. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
[TBL] [Abstract][Full Text] [Related]
25. Severe asthma as the initial clinical manifestation of IgG4-related disease: a retrospective clinical study.
Liu X; Shao C; Yu C; Huang H; Pan R; Xu K; Zhang X; Xu Z
BMC Pulm Med; 2022 Apr; 22(1):141. PubMed ID: 35413899
[TBL] [Abstract][Full Text] [Related]
26. Clinical manifestations, clinical course, and outcomes of immunoglobulin G4-related disease.
Phaopraphat K; Ngamjanyaporn P; Narongroeknawin P; Kasitanon N; Katchamart W
Int J Rheum Dis; 2020 Nov; 23(11):1468-1473. PubMed ID: 32808722
[TBL] [Abstract][Full Text] [Related]
27. Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse.
Lanzillotta M; Della-Torre E; Milani R; Bozzolo E; Bozzalla-Cassione E; Rovati L; Arcidiacono PG; Partelli S; Falconi M; Ciceri F; Dagna L
Arthritis Res Ther; 2018 Oct; 20(1):222. PubMed ID: 30285841
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids.
Yunyun F; Yu C; Panpan Z; Hua C; Di W; Lidan Z; Linyi P; Li W; Qingjun W; Xuan Z; Yan Z; Xiaofeng Z; Fengchun Z; Wen Z
Sci Rep; 2017 Jul; 7(1):6195. PubMed ID: 28733656
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial].
Cui TG; Hou FF; Ni ZH; Chen XM; Zhang FS; Zhu TY; Zhao XZ; Bao CD; Zhao MH; Wang GB; Qian JQ; Cai GY; Li YN; Lu FM; Mei CL; Zou WZ; Wang HY
Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):672-6. PubMed ID: 16202258
[TBL] [Abstract][Full Text] [Related]
30. Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients.
Wang L; Zhang P; Zhang X; Lin W; Tang H; Li J; Wang M; Liu X; Fei Y; Chen H; Peng L; Zhang L; Lai Y; Zeng X; Li X; Xue H; Zhao Y; Zhang F; Zhang W
Rheumatology (Oxford); 2019 May; 58(5):820-830. PubMed ID: 30561747
[TBL] [Abstract][Full Text] [Related]
31. IgG4-related disease administered dupilumab: case series and review of the literature.
Kanda M; Kamekura R; Sugawara M; Nagahata K; Suzuki C; Takano K; Takahashi H
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36894196
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis.
Lanzillotta M; Della-Torre E; Wallace ZS; Stone JH; Karadag O; Fernández-Codina A; Arcidiacono PG; Falconi M; Dagna L; Capurso G
Pancreatology; 2021 Oct; 21(7):1395-1401. PubMed ID: 34244040
[TBL] [Abstract][Full Text] [Related]
33. Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India.
Gupta N; Mathew J; Mohan H; Chowdhury SD; Kurien RT; Christopher DJ; Thangakunam B; Alexander M; Sivadasan A; Tamilarasi V; Valson AT; Gowri M; Kabeerdoss J; Danda D
Rheumatol Int; 2018 Feb; 38(2):203-209. PubMed ID: 28550399
[TBL] [Abstract][Full Text] [Related]
34. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes.
Lanzillotta M; Campochiaro C; Mancuso G; Ramirez GA; Capurso G; Falconi M; Dagna L; Della-Torre E
Rheumatology (Oxford); 2020 Sep; 59(9):2435-2442. PubMed ID: 32591828
[TBL] [Abstract][Full Text] [Related]
35. Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy.
Shang S; Cui S; Wang W; Wang C; Li P; Li W; Li Q
Front Endocrinol (Lausanne); 2022; 13():941215. PubMed ID: 36111292
[TBL] [Abstract][Full Text] [Related]
36. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
37. Rituximab for IgG4-related disease: a prospective, open-label trial.
Carruthers MN; Topazian MD; Khosroshahi A; Witzig TE; Wallace ZS; Hart PA; Deshpande V; Smyrk TC; Chari S; Stone JH
Ann Rheum Dis; 2015 Jun; 74(6):1171-7. PubMed ID: 25667206
[TBL] [Abstract][Full Text] [Related]
38. Emerging therapy options for IgG4-related disease.
Lanzillotta M; Fernàndez-Codina A; Culver E; Ebbo M; Martinez-Valle F; Schleinitz N; Della-Torre E
Expert Rev Clin Immunol; 2021 May; 17(5):471-483. PubMed ID: 33689549
[TBL] [Abstract][Full Text] [Related]
39. IgG4-related disease: features and treatment response in a multi-ethnic cohort in Singapore.
Fong W; Liew I; Tan D; Lim KH; Low A; Leung YY
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):89-93. PubMed ID: 29846168
[TBL] [Abstract][Full Text] [Related]
40. Clinical profiles differ in IgG4-related disease with and without allergy: a large case-control study in China.
Zhao Z; Liu Y; Bai M; Zeng Q; Wang Z; Chen D; Li Z; Su Y
Clin Exp Rheumatol; 2023 Sep; 41(9):1808-1814. PubMed ID: 36826798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
